About Protagonist Therapeutics, Inc.
https://www.protagonist-inc.comProtagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases.
CEO
Dinesh V. Patel
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 191
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Citigroup
Buy
BTIG
Buy
Truist Securities
Buy
HC Wainwright & Co.
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Grade Summary
Showing Top 6 of 12
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:9.4M
Value:$801.52M
FARALLON CAPITAL MANAGEMENT LLC
Shares:6.2M
Value:$528.09M
BLACKROCK INC.
Shares:5.76M
Value:$490.76M
Summary
Showing Top 3 of 315
About Protagonist Therapeutics, Inc.
https://www.protagonist-inc.comProtagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $4.71M ▼ | $51.13M ▲ | $-39.34M ▼ | -834.87% ▼ | $-0.62 ▼ | $-38.98M ▲ |
| Q2-2025 | $5.55M ▼ | $47.59M ▼ | $-34.77M ▼ | -626.96% ▼ | $-0.55 ▼ | $-41.74M ▼ |
| Q1-2025 | $28.32M ▼ | $47.63M ▲ | $-11.65M ▼ | -41.15% ▼ | $-0.19 ▼ | $-19.07M ▼ |
| Q4-2024 | $170.64M ▲ | $43.86M ▼ | $131.67M ▲ | 77.17% ▲ | $2.11 ▲ | $127.32M ▲ |
| Q3-2024 | $4.67M | $46.13M | $-33.21M | -710.37% | $-0.54 | $-40.81M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $576.12M ▲ | $701.69M ▼ | $56.25M ▲ | $645.44M ▼ |
| Q2-2025 | $570.47M ▼ | $718.01M ▼ | $49.99M ▼ | $668.02M ▼ |
| Q1-2025 | $574.36M ▲ | $742.13M ▼ | $53.08M ▼ | $689.05M ▲ |
| Q4-2024 | $418.91M ▼ | $744.73M ▲ | $69.43M ▼ | $675.29M ▲ |
| Q3-2024 | $468.72M | $603.86M | $71.94M | $531.91M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-39.34M ▼ | $-1.94M ▲ | $-58.55M ▼ | $5.66M ▲ | $-54.83M ▼ | $-2.02M ▲ |
| Q2-2025 | $-34.77M ▼ | $-28.78M ▼ | $54.81M ▲ | $2.92M ▼ | $28.95M ▼ | $-29.59M ▼ |
| Q1-2025 | $-11.65M ▼ | $125.36M ▲ | $-94.4M ▼ | $11.44M ▲ | $42.4M ▲ | $124.82M ▲ |
| Q4-2024 | $131.67M ▲ | $-29.18M ▼ | $-8.72M ▲ | $4.03M ▼ | $-33.87M ▲ | $-29.49M ▼ |
| Q3-2024 | $-33.21M | $-27.86M | $-208.71M | $12.05M | $-224.52M | $-28.64M |
Revenue by Products
| Product | Q1-2024 | Q2-2024 | Q3-2024 | Q4-2024 |
|---|---|---|---|---|
 Development Services | $0 ▲ | $10.00M ▲ | $10.00M ▲ | $0 ▼ |
CEO
Dinesh V. Patel
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 191
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Citigroup
Buy
BTIG
Buy
Truist Securities
Buy
HC Wainwright & Co.
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Grade Summary
Showing Top 6 of 12
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:9.4M
Value:$801.52M
FARALLON CAPITAL MANAGEMENT LLC
Shares:6.2M
Value:$528.09M
BLACKROCK INC.
Shares:5.76M
Value:$490.76M
Summary
Showing Top 3 of 315